Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study
Authors' conclusion
Risk of revision surgery is not increased in patients with inflammatory arthritis perioperatively exposed to TNFi.
Study context
- Population
- Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) or primary osteoarthritis (OA) undergoing total hip arthroplasty (THA), RIPO regional register, 2008–2019
- Exposure
- Perioperative TNF inhibitors (TNFi) vs non-bDMARD/tsDMARD vs OA
- Outcome
- Long-term THA survival (any revision surgery as endpoint)
- Follow-up
- Average 5 years
Methodological detailsregistry-based, regional arthroplasty register (RIPO)
- Registry-based
- Regional arthroplasty register (RIPO)
Main finding
As reported in the abstract
THA survival (any revision surgery)
- TNFi vs Non-bDMARD/tsDMARD: P = 0.713
- TNFi vs OA: P = 0.123
Observational data: associations, not effects.
Further findings
Revision surgery · latest available follow-up
Safety
Postoperative infection or aseptic loosening
- No significant differences among groups
Original publication
Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study. Semin Arthritis Rheum. Published 31 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →